(Q34644447)

3 August 2017

1 reference

title

Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1. (English)

1 reference

3 August 2017

1 reference

Yi Xiao

1

1 reference

3 August 2017

Xiaonan Dong

series ordinal

2

1 reference

3 August 2017

Ying-Hua Chen

series ordinal

3

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

3

1 reference

3 August 2017

193-200

1 reference

https://scigraph.springernature.com/pub.10.1385/ir:25:3:193

3 August 2017

0 references

cites work

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

12 December 2020

AIDS vaccines. Glimmerings of hope from the bottom of the well

1 reference

12 December 2020

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

1 reference

12 December 2020

Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya

1 reference

12 December 2020

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements

1 reference

12 December 2020

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

1 reference

12 December 2020

Immune correlates of protection from HIV and AIDS – more answers but yet more questions

1 reference

12 December 2020

CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.

1 reference

12 December 2020

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

12 December 2020

HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket

1 reference

12 December 2020

Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope

1 reference

12 December 2020

Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia

1 reference

12 December 2020

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

1 reference

12 December 2020

Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1

1 reference

12 December 2020

1 reference

12 December 2020

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

12 December 2020

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?

1 reference

12 December 2020

Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

1 reference

12 December 2020

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

12 December 2020

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Multifaceted Consequences of Anti-gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions

1 reference

12 December 2020

Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.

1 reference

12 December 2020

A vaccine for HIV type 1: the antibody perspective

1 reference

12 December 2020

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

12 December 2020

HIV vaccines: prospects and challenges.

1 reference

12 December 2020

The great escape - AIDS viruses and immune control

1 reference

12 December 2020

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection

1 reference

12 December 2020

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

12 December 2020

Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neut

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries

1 reference

12 December 2020

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

12 December 2020

Epitope vaccine: a new strategy against HIV-1

1 reference

12 December 2020

HIV type 1 coreceptors, neutralization serotypes, and vaccine development

1 reference

12 December 2020

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

1 reference

12 December 2020

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera.

1 reference

12 December 2020

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

12 December 2020

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines

1 reference

12 December 2020

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

12 December 2020

Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.

1 reference

12 December 2020

Back to primary school

1 reference

12 December 2020

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

12 December 2020

A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex

1 reference

12 December 2020

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

1 reference

12 December 2020

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma

1 reference

12 December 2020

Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody

1 reference

12 December 2020

Why do we not have an HIV vaccine and how can we make one? .

1 reference

12 December 2020

Identifiers

DOI

10.1385/IR:25:3:193

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference